Aptorum Group to Undergo Reverse Merger with DiamiR Biosciences, Resulting in 70% Dilution for Existing Shareholders and Name Change to Niki BioSolutions

summarizeSummary

Aptorum Group is executing a reverse merger with DiamiR Biosciences, leading to significant dilution for current shareholders, a new company name, and a strategic shift aimed at resolving going concern issues and leveraging DiamiR's diagnostic pipeline.

check_boxKey Events

• Reverse Merger with DiamiR Biosciences

  Aptorum Group will merge with DiamiR Biosciences Corp., with DiamiR becoming a wholly-owned subsidiary. The combined entity will be renamed 'Niki BioSolutions, Inc.' and will be reincorporated in Delaware.

• Significant Shareholder Dilution

  Existing Aptorum shareholders will own approximately 30% of the combined company, while DiamiR stockholders will own 70%, indicating substantial dilution for current APM investors.

• Proposed Reverse Stock Split

  Shareholders will vote on a reverse stock split (share consolidation) at a ratio between 2-for-1 and 10-for-1, intended to increase the per-share price and maintain Nasdaq listing compliance.

• Addressing Going Concern Doubts

  Both Aptorum and DiamiR have received 'going concern' qualifications from their auditors, highlighting the critical need for this merger to secure future operations and financing.

auto_awesomeAnalysis

Aptorum Group Ltd is undertaking a reverse merger with DiamiR Biosciences Corp., a molecular diagnostics company. This transaction is highly significant as existing Aptorum shareholders will own approximately 30% of the combined entity, while DiamiR stockholders will own 70%, representing substantial dilution. Both companies are currently facing 'going concern' doubts from their auditors, making this merger a critical strategic move to ensure continued operations and access to capital. The combined company will be renamed 'Niki BioSolutions, Inc.' and will be domiciled in Delaware. A reverse stock split is also proposed to maintain Nasdaq listing compliance, which is a common measure for companies with low share prices. The CEO's significant voting power (87.05%) ensures all merger-related proposals will pass, reducing execution risk for the transaction. This merger fundamentally alters Aptorum's business focus and ownership structure, aiming to leverage DiamiR's diagnostic technology and address the combined entity's financial viability.